Stereotactic Biopsy

Stereotactic biopsy is a minimally invasive neurosurgical procedure that uses image-guided coordinate targeting to advance a fine needle to a deep or eloquent brain lesion and obtain a small tissue sample for diagnosis. It allows tissue confirmation of lesions that would be hazardous to remove or reach by open surgery, and it is a workhorse diagnostic application of the stereotactic principle.

Definition

Stereotactic biopsy is the acquisition of a small tissue sample from an intracranial lesion using image-derived three-dimensional coordinates to guide a needle precisely to the target, performed to obtain a histopathological diagnosis.

Scope

This entry covers the purpose of stereotactic biopsy, its frame-based and frameless approaches, the concept of diagnostic yield, and the principal risk of hemorrhage. It is a reference-educational overview and does not provide procedural or treatment guidance.

Core questions

• When is biopsy preferred over open resection for a brain lesion?
• How does coordinate-based targeting reach deep or eloquent lesions safely?
• What is diagnostic yield and what factors affect it?
• What is the main procedural risk and how is it characterized?

Key concepts

• Frame-based and frameless targeting
• Diagnostic yield
• Needle trajectory planning
• Hemorrhagic complications
• Deep and eloquent-area lesions
• Histopathological diagnosis

Mechanisms

A target within the lesion is defined by coordinates derived from cross-sectional imaging, and a biopsy needle is advanced along a planned trajectory to that point, either using a rigid frame fixed to the skull or a frameless neuronavigation system registered to imaging. One or more tissue cores are taken for histopathological examination. The diagnostic value of the procedure is expressed as diagnostic yield — the proportion of biopsies that produce a usable diagnosis — while the principal procedural hazard is hemorrhage along the needle track or within the lesion.

Clinical relevance

Stereotactic biopsy provides tissue diagnosis for lesions that are deep, multifocal, or in eloquent regions where resection is not the first step, informing classification of intracranial disease. This entry describes how the procedure functions and how its performance is measured; it characterizes diagnostic methodology and is not guidance for individual care.

Evidence & guidelines

Observational series describe the procedure's performance: in a consecutive single-center series, Hakan and Aker (2015) reported on diagnostic yield, accuracy, non-diagnostic results, and hemorrhagic complications across 126 stereotactic cases, illustrating the trade-off between high diagnostic yield and a small but important risk of hemorrhage. Reported yields and complication rates vary across centers and lesion types.

History

Stereotactic biopsy developed directly from the coordinate-frame methods that defined stereotactic neurosurgery in the twentieth century, providing a low-morbidity route to tissue diagnosis of deep lesions (Gildenberg, 2009). The later addition of frameless neuronavigation broadened workflow options while preserving the coordinate-targeting principle.

Seminal works

• hakan-2015

Frequently asked questions

Why perform a biopsy instead of removing the whole lesion?

Some lesions are deep, multifocal, or located in eloquent areas where resection carries high risk; a stereotactic biopsy obtains a diagnosis with minimal disruption so that further management can be guided by the tissue result.

What is the main risk of a stereotactic brain biopsy?

The principal procedural risk is hemorrhage along the needle track or within the lesion; series report this as uncommon but clinically important, alongside a small chance of a non-diagnostic sample.